|   | 
                  
                       | 
                      | 
                    
                        
                            
                                | 
                                  
                                 | 
                             
                             |  
                            
                                
                                    
                                        
  
    
	  | 
   
  
    
        
          |   | 
          
              
                | 
                    µð¿Àº£Æ®¸®¿¡ÀÌ¿¬°í(Ä®½ÃÆ÷Æ®¸®¿Ã)_(1.5mg/30g)    
                    
                 | 
               
              
                | 
                     Àü¹®ÀǾàǰ | »èÁ¦  
                        
                    	
                    
                 | 
               
              
                | 
					  
                  
				  
                 | 
               
              
              
              
              
              |   |  
              
                
                    
                        | 
                      ¾Ë¸²:  | 
                      µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. | 
                     
                    | 
               
            
              
                
                   
                   
                   
                   
		   
                 | 
               
              
                | 
                  
                  
                 | 
               
              | 
            | 
         
       
       | 
   
    |  
  
    | 
      
     | 
     
  |                   
                                        | 
                                             | 
                                         
                            
                                
                            
                            
                              
                                                        
                              
                                                
                            
 |   
    | 
      
     | 
 
 |  
    
   
    | 
       
        À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
        ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
        À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
        ·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
       
     | 
   
  
     | 
   
  
  
    
      
  
    
       |  
      
        
          
            
                | Çã°¡Á¤º¸ | 
             
           
         | 
       
       |  
      
  
    | Ç׸ñ | 
    ³»¿ë | 
   
  
  
  
  
   
    û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå  »óÇÑ±Ý¾× | 
    
      
      
        
        644805151  
	    
	    
            [º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸] 
          
        
        
        
          
          
            \0 ¿ø/30g/°³(2020.11.01)(ÇöÀç¾à°¡)
            \11,733 ¿ø/30g/°³(2017.03.01)(º¯°æÀü¾à°¡)
        
          
            
	 
  	   
  	   
       
      
       
       
     
      
      
     
      
    
    
    
      
     [»óº´ÄÚµåÁ¶È¸]
      
      [Áúº´ÄÚµåÁ¶È¸]
     
     | 
   
   
    | ºü¸¥Á¶È¸ | 
    
      
     |   
   
  
  
  
   
    | Á¦Ç°¼º»ó | 
    ¹ÝÅõ¸íÇÑ Èò»ö ³»Áö ¹ÌȲ»öÀÇ ¿¬°íÁ¦  [Á¦ÇüÁ¤º¸ È®ÀÎ] |   
   
  
  
  
  
  
   
    | Æ÷À塤À¯Åë´ÜÀ§ | 
    ÀÚ»çÆ÷Àå´ÜÀ§ | 
   
  
  
  
  
  	
   
    | ÁÖ¼ººÐÄÚµå | 
    
      121530COM  
      
	  [µ¿ÀÏÇÑ ÁÖ¼ººÐÄڵ带 °¡Áø ¿À¸®Áö³¯ ¶Ç´Â Á¦³×¸¯ ÀǾàǰ Á¶È¸]
     | 
   
  
  
  
 
  
  
    
  
  
  
  
  
  
  
  
  
  
 
  
  
  
 
  
  
  
  
  
  
   
    | Çã°¡»çÇ× ¿ø¹®Á¶È¸ | 
    
      
	    [Çã°¡»çÇ× ¿ø¹®Á¶È¸] 
     | 
   
  
  
  
  
     
  
  
  
   
    | È¿´ÉÈ¿°ú | 
    
    [ÀûÀÀÁõ º° °Ë»ö] 
      
    
     
	 
      °Ç¼±(°æÁõ ¹× ÁßµîÁõ)
      
     | 
   
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
    
  
  
  
  
  
   
    | ¿ë¹ý¿ë·® | 
    
      * Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù. 
    
     
      
      
      [󹿾à¾î] 
      ¼ºÀÎ
  
ȯºÎ¿¡ 1ÀÏ 1-2ȸ(¾ÆÄ§, Àú³á) ¹Ù¸¥´Ù. ÃÖ´ë È¿°ú¸¦ À§Çؼ´Â 1ÀÏ 2ȸ »ç¿ëÇØ¾ß ÇÑ´Ù. 1ÁÖ¿¡ 100g(1ÀÏ ¾à 15gÀÌ»ó)À» ÃʰúÇÏ¿© »ç¿ëÇÏÁö ¾Ê´Â´Ù. Ä®½ÃÆ÷Æ®¸®¿ÃÀ» ÇÔÀ¯ÇÏ´Â ´Ù¸¥ ¾à°ú ÇÔ²² »ç¿ëÇÒ °æ¿ì, ÀÌ ¾àÀ» Æ÷ÇÔÇØ¼ ¸ðµç Ä®½ÃÆ÷Æ®¸®¿Ã ÇÔÀ¯ Á¦Á¦ÀÇ 1ÁÖÀÏ ÃÑÅõ¿©·®ÀÌ Ä®½ÃÆ÷Æ®¸®¿Ã 5mgÀ» ÃʰúÇØ¼´Â ¾È µÈ´Ù. 
     
      	
     | 
   
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
   
    | ±Ý±â | 
    1) ÀÌ ¾à ¹× ÀÌ ¾à ¼ººÐ¿¡ °ú¹ÎÁõ ¹× ±× º´·ÂÀÌ Àִ ȯÀÚ 
2) °íÄ®½·Ç÷Áõ µî Ä®½·´ë»ç Àå¾Ö ȯÀÚ 
3) ºñŸ¹Î D µ¶¼ºÀ» ³ªÅ¸³»´Â ȯÀÚ  | 
   
  
  
  
  
   
    | ½ÅÁßÅõ¿© | 
    ÀÌ ¾àÀº ÇÁ·ÎÇÊ·»±Û¸®ÄÝÀ» ÇÔÀ¯Çϰí ÀÖÀ¸¹Ç·Î ÀÌ ¼ººÐ¿¡ °ú¹ÎÇϰųª ¾Ë·¹¸£±â º´·ÂÀÌ Àִ ȯÀÚ¿¡´Â ½ÅÁßÈ÷ Åõ¿©ÇÑ´Ù.  | 
   
  
    
  
  
  
  
  
   
    | ÀÌ»ó¹ÝÀÀ | 
    
       ÀÌ»ó¹ÝÀÀÀÇ ºóµµ´Â ÀÓ»ó½ÃÇè ¹× ÀÚ¹ßÀû º¸°í¿¡¼ ³ª¿Â µ¥ÀÌÅ͸¦ Á¾ÇÕ ºÐ¼®ÇÏ¿© Æò°¡µÇ¾ú´Ù. 
°¡Àå ºó¹øÇÏ°Ô º¸°íµÈ ÀÌ»ó¹ÝÀÀÀº °¡·Á¿ò, ÇǺΠÀÚ±Ø, È«¹ÝÀ̾ú´Ù. 
Àü½Å ¹ÝÀÀ(°íÄ®½·Ç÷Áõ ¹× °íÄ®½·´¢)ÀÌ º¸°íµÈ ¹Ù ÀÖ´Ù. °ú·® Åõ¿©½Ã ÀÌ·¯ÇÑ ¹ÝÀÀÀÌ ¹ß»ýÇÒ À§ÇèÀÌ Áõ°¡ÇÑ´Ù. 
ÀÌ»ó¹ÝÀÀÀº MedDRA SOC¿¡ ÀÇÇØ ¿°ÅµÇ¸ç °³º°ÀûÀÎ ÀÌ»ó¹ÝÀÀÀº ºóµµ°¡ ³ôÀº ¼ø¼´ë·Î ³ª¿µÈ´Ù. µ¿ÀÏÇÑ ºóµµ ³»¿¡¼´Â ÁßÁõµµ°¡ °¨¼ÒÇÏ´Â ¼ø¼´ë·Î ³ª¿µÈ´Ù. 
¸Å¿ì ÈçÇÏ°Ô (¡Ã1/10), ÈçÇÏ°Ô (¡Ã1/100¿¡¼ <1/10) 
ÈçÇÏÁö ¾Ê°Ô (¡Ã1/1,000¿¡¼ <1/100), µå¹°°Ô (¡Ã1/10,000¿¡¼ <1/1,000), ¸Å¿ì µå¹°°Ô (<1/10,000) 
 
  
  |   ºóµµ   |  
    ÀÌ»ó¹ÝÀÀ   |  
   
  
  |   °¨¿°   |  
   
  
  |   ÈçÇÏÁö ¾Ê°Ô (¡Ã1/1,000¿¡¼ <1/100)   |  
    ¸ð³¶¿°   |  
   
  
  |   ¸é¿ª°è ÀÌ»ó   |  
   
  
  |   µå¹°°Ô (¡Ã1/10,000¿¡¼ <1/1,000)   |  
    °ú¹ÎÁõ   |  
   
  
  |   ´ë»ç ¹× ¿µ¾ç ÀÌ»ó   |  
   
  
  |   µå¹°°Ô (¡Ã1/10,000¿¡¼ <1/1,000)   |  
    °íÄ®½·Ç÷Áõ   |  
   
  
  |   ÇǺΠ¹× ÇÇÇÏÁ¶Á÷ ÀÌ»ó   |  
   
  
  |   ÈçÇÏ°Ô (¡Ã1/100¿¡¼ <1/10)   |  
    °Ç¼±ÀÇ ¾ÇÈ, ÇǺο°, È«¹Ý, ¹ÚÇÇ,  ÀÛ¿°¨, ÇǺΠÀÚ±Ø, °¡·Á¿ò   |  
   
  
  |   ÈçÇÏÁö ¾Ê°Ô (¡Ã1/1,000¿¡¼ <1/100)   |  
    ¹ßÁø*, ÇǺΠ°ÇÁ¶   |  
   
  
  |   µå¹°°Ô (¡Ã1/10,000¿¡¼ <1/1,000)   |  
    ±¤°ú¹ÎÁõ, ÇǺΠºÎÁ¾, µÎµå·¯±â,  Áö·ç¼º ÇǺο°   |  
   
  
  |   ½ÅÀå ¹× ¿ä°ü ÀÌ»ó   |  
   
  
  |   µå¹°°Ô (¡Ã1/10,000¿¡¼ <1/1,000)   |  
    °íÄ®½·´¢   |  
   
  
  |   ÀϹÝÀû ÀÌ»ó ¹× Åõ¿©ºÎÀ§ »óÅ   |  
   
  
  |   ÈçÇÏ°Ô (¡Ã1/100¿¡¼ <1/10)   |  
    Åõ¿©ºÎÀ§ ÅëÁõ   |  
   
  
  |   ÈçÇÏÁö ¾Ê°Ô (¡Ã1/1,000¿¡¼ <1/100)   |  
    Åõ¿©ºÎÀ§ »ö¼ÒÄ§Âø º¯È   |  
   
 
* È«¹Ý¼º ¹ßÁø, ¹Ý±¸Áø¹ßÁø, È«¿ª¸ð¾ç¹ßÁø, ±¸Áø¹ßÁø, ³óÆ÷¹ßÁø°ú °°Àº ´Ù¾çÇÑ À¯ÇüÀÇ ¹ßÁø ¹ÝÀÀÀÌ º¸°íµÇ¾ú´Ù. 
      
     | 
   
        
  
  
    
   
    | »óÈ£ÀÛ¿ë | 
    ÀÌ ¾à¿¡ ´ëÇÑ »óÈ£ÀÛ¿ëÀº ¿¬±¸µÇÁö ¾Ê¾Ò´Ù.  | 
   
  
    
  
  
       	
  
     
  
  
  
  
  
  
  |  
     
   
  
    
       |  
      
        
          
            
                | Á¤º¸¿ä¾à |         
             
           
         | 
             	    
       |  
      | 
  
    µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
    
  
  
    
  
   |  
     
   
  
    
       |  
      
        
          
            
                | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |         
             
           
         | 
             	    
       |  
      | 	 |  
     
   
  
    
       |  
      
        
          
            
                | Á¦Ç°Á¤º¸ |            
             
           
         | 
             	  
       |  
       |  
     
   
  
    
       |  
      
        
          
            
                | º¹¾àÁ¤º¸ |            
             
           
         | 
             	  
       |  
      
  
    | Ç׸ñ | 
    ³»¿ë | 
   
   
    | LACTmed ¹Ù·Î°¡±â | 
    
      
        [¹Ù·Î°¡±â]
     | 
     
  
  
   
    | ¾à¸®ÀÛ¿ë | 
    
       
      À¯·áÁ¤º¸ÀÔ´Ï´Ù.
       
     | 
     
  
  
  
   
    | Ãà¾àº¹¾àÁöµµ | 
    
     
    À¯·áÁ¤º¸ÀÔ´Ï´Ù.
    
     | 
   
       
  
  
   
    | º¹¾àÁöµµ | 
    
     
    À¯·áÁ¤º¸ÀÔ´Ï´Ù.
    
     | 
   
                                                          															
  
   
  
  
   
    | ÀӺο¡´ëÇÑÅõ¿© | 
    
      
      
        
	      
	      
	        | *  | 
	        
	          ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù. 
	         | 
	         
	       
	       | 
	   
	  
	    |   | 
	   
	  
	    
	      FDA : Cµî±Þ 
				        	
					  
					
	   | 
	  
	  
	  
	     
	     
	     
	     
	     
	     
	   | 
	 
	
	  
	      
	      
	        | *  | 
	        
	          »ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
	         | 
	         
	      
	        | *  | 
	        
	          ¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
	         | 
	         
	       
	   | 
	 
       
     | 
   
  
  
  	   
  
  	   
  
  	   
  
  
     
      | Pharmacokinetics | 
      
       
      À¯·áÁ¤º¸ÀÔ´Ï´Ù.
      
       |   
     
  
  
  
  
  
  
  	
  
  
  	
  
  
   
    | Á¦Çüº° º¹¾àÁöµµ | 
    [¿¬°í] | 
   
  
  
   
    | º¸°ü»ó ÁÖÀÇ | 
    
      
    	
     | 
   
  
  
   
    | Á¶Á¦½Ã ÁÖÀÇ | 
    
      
    	
     | 
      
 
 |  
     
   
  
    
       |  
      
        
          
            
                | ½É»çÁ¤º¸ |            
             
           
         | 
             	  
       |  
       |  
     
     
  
    
       |  
      
        
          
            
                | ÇмúÁ¤º¸ |          
             
           
         | 
             	  
       |  
      
  
    | Ç׸ñ | 
    ³»¿ë | 
   
  
    | DUR (ÀǾàǰ»ç¿ëÆò°¡) | 
    º´¿ë±Ý±â :
     
	 °í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
	 
	  [»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]										
	  ¿¬·É´ë±Ý±â :
      °í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
      
       [¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
       
       
        
        
     | 
   
  
   
    | Mechanism of Action | 
    
       Calcipotriol¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ The precise mechanism of calcipotriol in remitting psoriasis is not well-understood. However, it has been shown to have comparable affinity with calcitriol for the Vitamin D receptor, while being less than 1% as active as the calcitriol in regulating calcium metabolism. The Vitamin D receptor (VDR) belongs to the steroid/thyroid receptor superfamily, and is found on the cells of many different tissues including the thyroid, bone, kindney, and T cells of the immune system. T cells are known to play a role in psoriasis, and it is thought that the binding of calcipotriol to the VDR modulates the T cells gene transcription of cell differentiation and proliferation related genes. 
     | 
   
  
   
    | Pharmacology | 
     
       Calcipotriol¿¡ ´ëÇÑ Pharmacology Á¤º¸ Calcipotriene is a synthetic analog of vitamin D. In humans, the natural supply of vitamin D depends mainly on exposure to the ultraviolet rays of the sun for conversion of 7-dehydrocholesterol to vitamin D3 (cholecalciferol) in the skin. 
     | 
   
  
   
    | Absorption | 
    
       Calcipotriol¿¡ ´ëÇÑ Absorption Á¤º¸ Clinical studies with radiolabeled ointment indicate that approximately 6% (+3%, SD) of the applied dose of calcipotriene is absorbed systemically when the ointment is applied topically to psoriasis plaques or 5% (+2.6%, SO) when applied to normal skin. 
     | 
   
  
   
    | Pharmacokinetics | 
    
       CalcipotriolÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á 
- ÀÛ¿ë¹ßÇö½Ã°£ : 1ÁÖ
 - ÃÖ´ëÈ¿°ú ¹ßÇö½Ã°£ : 8ÁÖ
 - ÀÛ¿ëÁö¼Ó½Ã°£ : ¹Ýº¹ Àû¿ë : 4ÁÖ
 - Èí¼ö : ±¹¼Ò Àû¿ë : Á¤»ó ÇǺο¡ Àû¿ë½Ã ¾à 5%, °Ç¼± plaque¿¡ Àû¿ë½Ã ¾à 6%°¡ Àü½ÅÀûÀ¸·Î Èí¼öµÈ´Ù.
 - ´ë»ç : Àü½ÅÀûÀ¸·Î Èí¼öµÈ ¾à¹°Àº Àû¿ë 24½Ã°£ À̳»¿¡ ÁÖ·Î °£¿¡¼ ºñȰ¼ºÇü ´ë»çü·Î ´ë»çµÈ´Ù.
  
     | 
   
  
   
    | Biotransformation | 
    
       Calcipotriol¿¡ ´ëÇÑ Biotransformation Á¤º¸ Hepatic. Calcipotriene metabolism following systemic uptake is rapid, and occurs via a similar pathway to the natural hormone. The primary metabolites are much less potent than the parent compound. 
     | 
   
  
   
    | Toxicity | 
    
       Calcipotriol¿¡ ´ëÇÑ Toxicity Á¤º¸ Topically applied calcipotriene can be absorbed in sufficient amounts to produce systemic effects. Elevated serum calcium has been observed with excessive use of calcipotriene. 
     | 
   
  
   
    | Drug Interactions | 
    
       Calcipotriol¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Not Available 
     | 
   
  
   
    CYP450  Drug Interaction | 
    
      [CYP450 TableÁ÷Á¢Á¶È¸] 
     | 
   
  
   
    | Drug Target | 
    
      
      [Drug Target]
     | 
   
  
   
    | Description | 
    
       Calcipotriol¿¡ ´ëÇÑ Description Á¤º¸ Calcipotriol (INN) or calcipotriene (USAN) is a sythetic derivative of calcitriol or Vitamin D. 
     | 
   
  
   
    | Dosage Form | 
    
       Calcipotriol¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Cream	TopicalOintment	TopicalShampoo	Topical 
     | 
   
  
   
    | Drug Category | 
    
       Calcipotriol¿¡ ´ëÇÑ Drug_Category Á¤º¸ Antipsoriatic AgentsDermatologic AgentsVitamin D3 Receptor inhibitor 
     | 
   
  
   
    | Smiles String Canonical | 
    
       Calcipotriol¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CC(C=CC(O)C1CC1)C1CCC2C1(C)CCCC2=CC=C1CC(O)CC(O)C1=C 
     | 
   
  
   
    | Smiles String Isomeric | 
    
       Calcipotriol¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ C[C@H](\C=C\[C@@H](O)C1CC1)[C@H]1CC[C@H]2[C@@]1(C)CCC\C2=C\C=C1\C[C@H](O)C[C@@H](O)C1=C 
     | 
   
  
   
    | InChI Identifier | 
    
       Calcipotriol¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C27H40O3/c1-17(6-13-25(29)20-8-9-20)23-11-12-24-19(5-4-14-27(23,24)3)7-10-21-15-22(28)16-26(30)18(21)2/h6-7,10,13,17,20,22-26,28-30H,2,4-5,8-9,11-12,14-16H2,1,3H3/b13-6+,19-7-,21-10- 
     | 
   
  
   
    | Chemical IUPAC Name | 
    
       Calcipotriol¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R)-5-cyclopropyl-5-hydroxypent-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol 
     | 
   
    
  |  
     
     
  
    
       |  
      
        
          
            
                | »ç¿ëÀÚÄÁÅÙÃ÷ |           
             
           
         | 
             	  
       |  
       |  
     
         
 
     | 
   
   
     | 
   
  
    
      
        
          
            
              - 
                ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2020-11-19
              
 
              - 
                
                 º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
                
              
     
             
         |                 
       
     |       
          
                
                    
                       ¾Ë¸² | 
                       
                      »ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù.  | 
                    
                    | 
               
      
      
                
                    
                       °æ°í | 
                     
                      µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù. 
                          Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â 
                          Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
                            ¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
                          ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
 | 
  
                    | 
               
  
 
  
    ¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é 
    ¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
   
  
 
  º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
 
  
  |  
                           
                         | 
                       
                      | 
                   |